Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Abstract:
--Appointment Expands Leadership Team and Strengthens Commercial Focus--

BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development

Philadelphia, PA | Posted on December 2nd, 2008

BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over a decade of strategic business development experience with leading biotechnology and genomics companies. He will focus on expanding BioNanomatrix's commercial and research partnerships for its breakthrough nanoscale whole genome technology platform in multiple markets, including research, diagnostics and personalized medicine.

"Gary's background and experience are close to ideal for our newly created senior business development position, and we are very pleased to have him on board," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "Gary's scientific expertise is directly relevant to our end-user markets and his extensive business development and alliance management experience should be invaluable as we expand our network of collaborations and commercial partnerships."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.

"This is an exciting time to join BioNanomatrix as the company is advancing a potentially transformative single-molecule, whole genome sorting and imaging technology that will enable scientists to analyze clinically relevant DNA sequence variation, copy number and positional information, and to do so much faster, more cost-effectively and with far better resolution than existing methods," said Dr. Zweiger. "There are many possible applications for our technology, and I look forward to working with the BioNanomatrix team to expand the company's growing list of partnerships and help establish new opportunities for growth."

Prior to joining BioNanomatrix, Dr. Zweiger was senior director of business development at Affymetrix, where he managed collaborations, developed new business opportunities and secured revenue-generating research partnerships. Previously, he was director of business development for Applied Biosystems' Cell and Molecular Biology division, where he managed collaborations and business development activities for the company's PCR, DNA sequencing, RNA interference and cell biology businesses. Prior to Applied Biosystems, Dr. Zweiger was at Agilent Technologies, where he held positions of increasing responsibility, directing efforts to identify, assess and secure new business opportunities. Earlier in his career, Dr. Zweiger served as a strategic advisor and consultant to biotechnology and genomics companies and to the financial community. He has published a general audience book on sequencing the human genome, authored numerous scientific publications and holds seven patents. Dr. Zweiger received a Ph.D. in genetics and a B.S. in biological sciences from Stanford University and completed a post-doctoral fellowship in molecular oncology at Genentech Inc.

####

About BioNanomatrix, Inc.
BioNanomatrix isdeveloping breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.

For more information, please click here

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners
212 918-4650

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

Photon recycling The key to high-efficiency perovskite solar cells January 14th, 2022

NSF funds Rice effort to measure, preserve quantum entanglement: Physicist Guido Pagano wins CAREER Award to develop tools for quantum computing January 14th, 2022

Tuning the bonds of paired quantum particles to create dissipationless flow: A tunable platform made from atomically thin materials may help researchers figure out how to create a robust quantum condensate that can flow without losing energy January 14th, 2022

Nanomedicine

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

Preserving the goods: A new technique for isolating intact lysosomes from cell cultures: Scientists advance the study of fragile digestive organelles by developing strategy to rapidly extract them from cells using magnetic nanoparticles January 7th, 2022

Announcements

Nanostructures get complex with electron equivalents: Nanoparticles of two different sizes break away from symmetrical designs January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

The free-energy principle explains the brain January 14th, 2022

Appointments/Promotions/New hires/Resignations/Deaths

The National Space Society Mourns the Passing of Robert Krone, Founder of the Kepler Space Institute: Krone's Visionary and Humanistic Approach to the Study of Space Communities and Settlement Was Unique September 22nd, 2021

Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project